上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注去年哪家美股biotech风头最盛,候选者里一定有Summit(SMMT)的名字。如今,summit在发布2024年财报的同时,再度传出了令人联想甚多的公告:Summit将会把其从康方引进的依沃西单抗(AK112)与辉瑞的ADC药物进行联用,共同开展接下来的临床试验,并且在公告中,对ADC的用词是“several”,即...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.